You are here » Home » Companies » Company Overview » Anuh Pharma Ltd

Anuh Pharma Ltd.

BSE: 506260	Sector: Health care
NSE: N.A.	ISIN Code: INE489G01022

BSE 00:00 | 26 May

96.40

-0.45
(-0.46%)

OPEN

97.00

HIGH

97.70

LOW

94.00

NSE 05:30 | 01 Jan

Anuh Pharma Ltd

Add to Watchlist | Add to Portfolio

OPEN	97.00
PREVIOUS CLOSE	96.85
VOLUME	10966
52-Week high	154.90
52-Week low	84.60
P/E	15.80
Mkt Cap.(Rs cr)	483
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	97.00
CLOSE	96.85
VOLUME	10966
52-Week high	154.90
52-Week low	84.60
P/E	15.80
Mkt Cap.(Rs cr)	483
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

Anuh Pharma Ltd. (ANUHPHARMA) - News Sector

Sequent Scientific tanks 17% on weak Q4; stock down 70% from 52-wk high

11.34 am | 26 May 2022 | Business Standard

The company said the macro environment continues to be challenging due to volatility in costs and disruptions across supply chains.
Torrent Pharma rallies 9% on 1:1 bonus issue plan, dividend of Rs 23/share

9.38 am | 26 May 2022 | Business Standard

In Q4, the company posted net loss of Rs 118 crore against profit of Rs 324 crore in the year ago quarter
Torrent Pharma posts Rs 118 cr Q4 loss vs Rs 324 cr profit a year ago

11.37 pm | 25 May 2022 | Business Standard

The red line comes amid headwinds in EU operatopns and discontinuation of liquids business in the US; revenue, however, grows by 10%
Stocks to Watch: Adani Ports, Strides, Metropolis, RITES, Zee, Balrampur

7.42 am | 25 May 2022 | Business Standard

Stocks to Watch Today: Sugar and FMCG stocks likely to be in focus as govt limits sugar exports and exempts customs duty on agri cess. Apollo Hospital...
Divis Labs sheds 14% in two days, hits 52-week low post Q4 results

10.02 am | 24 May 2022 | Business Standard

The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity ...
Amazon, Flipkart in talks to buy stake in $1 bn diagnostic chain Metropolis

12.45 am | 21 May 2022 | Bloomberg

Metropolis runs more than 3,000 diagnostics centers as well as pathology laboratories in India and Africa
Board evaluating Sebi penalty of Rs 1 crore, says Fortis Healthcare

11.33 pm | 20 May 2022 | Business Standard

Market regulator SEBI slapped a fine on Fortis Healthcare subsidiaries on account of fund diversion by erstwhile promoters
Zydus Lifesciences Q4 net dips to 24% Rs 397 cr, revenue up 5%

11.31 pm | 20 May 2022 | Business Standard

Company says operational performance came amid geopolitical turmoil resulting in supply chain challenges and inflationary pressures
Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%

2.33 pm | 20 May 2022 | Business Standard

The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).
Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

1.08 am | 20 May 2022 | Business Standard

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
Dr Reddy's plans new brands in Russia, says no issue with funds in country

12.55 am | 20 May 2022 | Business Standard

The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
Lupin slips 9%, hits 2-year low on disappointing March quarter results

9.39 am | 19 May 2022 | Business Standard

Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
How Prathap Chandra Reddy propelled Apollo Hospitals into a new orbit

9.35 pm | 18 May 2022 | Business Standard

The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
We aim to test 500,000 patients a day in 5 years: Dr Lal PathLabs CMD

9.25 pm | 18 May 2022 | Business Standard

Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

9.22 pm | 18 May 2022 | Business Standard

'Cipla has so many capabilities that for anything we need to do, we say we can do it'
Rejuvenating Cipla: After global expansion, acquisitions on cards

9.18 pm | 18 May 2022 | Business Standard

Having consolidated its presence across geographies, the pharma major is looking at acquisitions
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

3.16 pm | 18 May 2022 | Business Standard

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results

9.52 am | 18 May 2022 | Business Standard

In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

1.47 am | 18 May 2022 | Business Standard

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations

12.42 pm | 17 May 2022 | Business Standard

Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...